pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 31 Non-oncology: 20
Oncology: 11
Under Consideration for Negotiation 20 Non-oncology: 12
Oncology: 8
Completed Negotiations 373 With Letter of Intent: 320
Without agreement: 53
Negotiations That Were Not Pursued 76

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Lonsurf Taiho Pharma Canada Inc. metastatic Gastric Cancer
Trintellix Lundbeck Canada Inc. Major Depressive Disorder
Adcetris Seattle Genetics Inc. Peripheral T-Cell Lymphoma
Kisqali Novartis Pharmaceuticals Canada Inc. Advanced or Metastatic Breast Cancer
Lynparza AstraZeneca Canada Inc. Ovarian Cancer

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Riximyo Sandoz Canada Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma
Nivestym Pfizer Canada ULC Prevention or treatment of neutropenia in various indications
Ruxience Pfizer Canada ULC Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks